J70.3

Clinical Causes: Prolonged use of certain medications such as amiodarone, methotrexate, and nitrofurantoin. Certain chemotherapy drugs that are known to affect lung tissue. Long-term use of antibiotics or anti-inflammatory drugs with potential pulmonary side effects. Exposure to drugs or substances that may induce an immune response, leading to lung inflammation. In some cases, the exact drug responsible may not be identified, and other environmental or genetic factors could play a role.

Key Symptoms: Persistent cough that does not go away. Shortness of breath, especially during exertion. Fatigue and general weakness. Chest discomfort or pain. Unintentional weight loss in some cases. Crackling or velcro-like sounds heard during lung auscultation. Clubbing of fingers, which indicates long-term oxygen deficiency.

Diagnosis Path: Diagnosing chronic drug-induced interstitial lung disorders involves a combination of clinical assessments and tests. Doctors typically start with a detailed medical history, focusing on medication use. Imaging studies, like high-resolution computed tomography (HRCT), can reveal patterns of lung tissue scarring or inflammation characteristic of this condition. Pulmonary function tests evaluate how well the lungs are working by measuring airflow and oxygen exchange. In some cases, a lung biopsy may be performed to confirm the diagnosis and rule out other causes of interstitial lung disease. Additional tests, including blood work and oxygen level assessments, help gauge the severity and impact on the body.

Treatment Protocols: Management of this condition involves several strategies aimed at stopping or reducing further lung damage. The first step often includes discontinuing the offending medication, under medical supervision. Corticosteroids or other anti-inflammatory drugs may be prescribed to reduce lung inflammation. Supportive care, such as supplemental oxygen and pulmonary rehabilitation, helps improve breathing and quality of life. In severe cases where fibrosis has developed, additional interventions such as lung transplantation may be considered. Regular monitoring and follow-up are critical to assess disease progression and response to treatment.